$Arcutis Biotherapeutics (ARQT.US)$
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
Positive
▪️Q4 2024 revenue grew 366% YoY to $63 million
▪️Full-year 2024 revenue increased 449% YoY to $160 million
▪️Strong quarter-over-quarter growth of 41% in Q4 2024
▪️Robust liquidity position of $329 million including available debt
▪️Option to re-draw $100 million deb...
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
Positive
▪️Q4 2024 revenue grew 366% YoY to $63 million
▪️Full-year 2024 revenue increased 449% YoY to $160 million
▪️Strong quarter-over-quarter growth of 41% in Q4 2024
▪️Robust liquidity position of $329 million including available debt
▪️Option to re-draw $100 million deb...
2
$Caribou Biosciences (CRBU.US)$
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
Sunday, 12th January at 7:05 pm
-- CB-010 GALLOP Phase 1 trial initiated in lupus --
-- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 --
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 --
-- Sri Ryali appointed chief fi...
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
Sunday, 12th January at 7:05 pm
-- CB-010 GALLOP Phase 1 trial initiated in lupus --
-- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 --
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 --
-- Sri Ryali appointed chief fi...
2
“The key to trading success is emotional discipline. If intelligence were the key, there would be a lot more people making money trading. … You must learn to follow the market and accept it for what it is, rather than what you want it to be.” – Mark Douglas
24
3
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
60
25
7
Charting Lessons: Sami Abusaad - Strategic Swing Trader
All about stocks: Investopedia
Stock Sites (these are very useful if you are serious about trading). Stock Trading 101: K Different Sites needed for Stock Trading. NOTE:Make sure you save this. I won't answer questions which can be foundhere or in the other stock education
Stock Trading 101 Part A: The Cognitive Psychology involved in Stock Trading - DrJaguar8
...
All about stocks: Investopedia
Stock Sites (these are very useful if you are serious about trading). Stock Trading 101: K Different Sites needed for Stock Trading. NOTE:Make sure you save this. I won't answer questions which can be foundhere or in the other stock education
Stock Trading 101 Part A: The Cognitive Psychology involved in Stock Trading - DrJaguar8
...
20
1
8